Table 1.

Model input data

	Linezolid	Vancomycin	Daptomycin	Data source
Clinical inputs
First-line treatment
Success, %	89.5	89.5	89.5a	Itani et al7,28
Failure or discontinuation, %b	10.5	10.5	10.5	(Calculated from above)
Second-line treatment
Success, %	100	100	100	Assumption
Resource inputs
Hospital stay, days	4.5	4.5	4.5	Barrett et al16
Hospital stay due to failure or discontinuation, additional daysb	5	5	5	Edelsberg et al27
Empiric antibiotic therapy, days	2	2	2	De Cock et al,21 Schurmann et al23
Definitive antibiotic therapy, days	12	12	12	Weigelt et al,10 Liu et al1
IV therapy, days	2.5	12	12
Oral therapy, days	9.5	0	0
Intravenous doses per day	2	2	1	Product label,2 Tice46
Oral doses per day	2	0	0	Product label2
ID physician inpatient visits	1	1	1	Tice et al,43 assumption
ID physician office visits	1	1	1	Tice et al,43 assumption
Outpatient laboratory work	1	1	1	Tice46
Outpatient parenteral antibiotic days	0	9.5	9.5	Calculated from above, also consistent with Itani et al7
PICC placement	0	1	1	Tice46
PICC complications	0	1c	1c	Tice et al,31 Moureau et al30

Notes:

^aAssumed to be same as linezolid/vancomycin for the base-case analysis; no direct trial comparison with linezolid and daptomycin;

^bdiscontinuation due to adverse event;

^cPICC complication costs will be added to all patients undergoing PICC placement. These costs are further detailed in Table 2.

Abbreviations: ID, infectious disease; IV, intravenous; PICC, peripherally inserted central catheter.